Cathepsin K inhibitors: A novel target but promising approach in the treatment of osteoporosis

Current Drug Targets

Volumn 14, Issue 13, 2013, Pages 1591-1600

  Helali, Asadul Mazid ^a   Iti, Farhana Matin ^b   Mohamed, Isa Naina ^c  

^a Gonoshasthya Samajvittik Medical College and Hospital   (Bangladesh)

^b RAJSHAHI MEDICAL COLLEGE   (Bangladesh)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Bone remodeling; Bone resorption; Bone turnover markers; Cathepsin K; Osteoclast; Osteoporosis; Selective cathepsin K inhibitors

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ATORVASTATIN; BALICATIB; BONE MORPHOGENETIC PROTEIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN B; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; CYTOCHROME P450 3A4; GELATINASE B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MIV 701; MIV 710; ODANACATIB; ONA 5334; OSTEOCLAST DIFFERENTIATION FACTOR; PARACETAMOL; PARATHYROID HORMONE; PLACEBO; RELACATIB; SOMATOMEDIN C; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; CYSTEINE PROTEINASE INHIBITOR;

BONE DENSITY; BONE FRAGILITY; BONE REMODELING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME ACTIVITY; HUMAN; HYPERTENSION; MORPHEA; MULTICENTER STUDY (TOPIC); NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROTEIN EXPRESSION; PRURITUS; PYCNODYSOSTOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; FEMALE; METABOLISM; OSTEOCLAST; OSTEOPOROSIS, POSTMENOPAUSAL;

ANIMALS; BONE DENSITY; BONE RESORPTION; CATHEPSIN K; CLINICAL TRIALS AS TOPIC; COLLAGEN TYPE I; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84887387835     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990202     Document Type: Review

References (87)

1. Burr DB. Introduction Bone turnover and fracture risk. J Musculoskel Neuron Interact 2003; 3(4): 408-09.
2. Castrillon JLP, Pinacho F, Luis DD, Menendez ML, Laita ADN. Odanacatib, a New Drug for the Treatment of Osteoporosis:Review of the Results in PostmenopausalWomen. J Osteoporos 2010; 10: 1-5.
3. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000; 17(1):1-45. Available at: http://consensus.nih.gov/2000/2000Osteoporosis111PDF.pdf. [accessed May 24, 2013].
4. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360: 53-62.
5. Society For Women Health Research; Sex Differences in Osteoporosis. Available at: http://www.womenshealthresearch.org/site/DocServer/SexDifferencesOsteoporosis.pdf?docID=1321 [accessed May 24, 2013].
6. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Public Health Service, Office of the Surgeon General, 2004.
7. Pathophysiology of Osteoporosis, In: Osteoporosis management, Module 3. CME program supported and arranged by American Medical Association in 2004. ACCMA, USA, 2004-2005; pp. 1-9.
8. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-64. Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14715483 [accessed May 25, 2013].
9. Menopause and osteoporosis. Available at: http://my.clevelandclinic.org/disorders/menopause/hic_menopause_and_osteoporosis.aspx [accessed May 25, 2013].
10. Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol 2001; 26: 79-94.
11. Gianoukakis AG, Smith TJ. The Role of Cytokines in the Pathogenesis of Endocrine Disease. Can J Diabetes 2004; 28(1): 30-42.
12. Pérez-Castrillón JL, Andres-Calvo M, Izquierdo-Delgado E, Mendo M, Luis DD, Dueñas-Laita A. Celiac Disease and Osteoporosis: A Review. The Open Bone Journal 2009; 1: 23-27.
13. Khosla S. Minireview: The OPG/RANKL/RANK System. Endocrinology 2001; 142(12): 5050-5.
14. Danka Greeviae D, Kataviae D, Lukiae IK, et al. Cellular and Molecular Interactions between Immune System and Bone. CMJ 2001; 42: 384-92.
15. Kalanjati VP. Immunological Aspect on Bone Cells. Folia Medica Indonesiana 2005; 41(4): 313-19.
16. Stoch SA, Wagner JA. Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy Development 2008; 83(1): 172-76.
17. Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast Activity and Subtypes as a Function of Physiology and Pathology- Implications for Future Treatments of Osteoporosis. Endocr Rev 2011; 32(1): 31-63.
18. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008; 42: 200-11.
19. Bromme D, Wilson S. In: Role of Cysteine Cathepsins in Extracellular Proteolysis; Parks WC, Mecham RP, Ed. Extracellular Matrix Degradation, Berlin: Springer-Verlag 2011; pp 29-51.
20. Chen W, Abe SY, Li M, Wang Y, Shao J, Li YP. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 2007; 16(4): 410-23.
21. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-39.
22. New Developments in Hormone Replacement Therapy; Harvard Health Education. Available at: http://www.health.harvard.edu/fhg/fhgupdate/B/B1.shtml [accessed May 24, 2013].
23. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. Jama 2003; 289: 537-8.
24. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-61.
25. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278-81.
26. Vanden WT, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007; 19: 315-22.
27. Marcus R, Wong M. Health H, Stock JL. Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. Endocr Rev 2002; 23(1): 16-37.
28. Hodgson SF, Watts NB, Bilezikian JP, et al. for the AACE OsteoporosisTask Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-64.
29. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9: 84-01.
30. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Available at: http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf [accessed june 1, 2013].
31. Bromme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995; 376: 379-84.
32. Xue Y, Cai T, Shi S, Wang W, Zhang Y, Mao T, Duan X. Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011. Orphanet J Rare Dis 2011; 6(20): 1-10.
33. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012; 27(11): 2251-58.
34. Aline G. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011; 7: 447-56.
35. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J. Bone Miner Res 2003; 18: 222-30
36. Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997; 57: 5386-90.
37. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM. Expression and regulation of cathepsin K in skin fibroblasts. Exp. Dermatol 2009; 18: 596-602.
38. Dickinson DP. Cysteine peptidases of mammals: Their Biological Roles and Potential Effects in the Oral Cavity and Other Tissues in Health and Disease. CROBM 2002; 13(3): 238-75.
39. Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene 2009; 446: 90-98.
40. Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis 1996; 2: 70-76.
41. Garnero P, Borel O, Byrjalsen I, et al. The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases. The Journal of Biological Chemistry 1998; 273: 32347-52.
42. Lecaille F, Bromme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008; 90: 208-26.
43. Shi GP, Chapman HA, Bhairi SM, Deleeuw C, Reddy VY, Weiss SJ. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995; 357: 129-34.
44. Bromme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995; 376: 379-84.
45. Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996; 271: 12511-16.
46. Atley, LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 2000; 26: 241-47.
47. Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 1998; 331: 727-32.
48. Hou WS, Li Z, Gordon RE, et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001; 159: 2167-77.
49. Gelb BD, Bromme D, Desnick, RJ. Pycnodysostosis: Cathepsin K deficiency. In: Sriver CR, Beaudet AL, Valle D, Sly WCS, Ed. The Metabolic and Molecular Bases of Inherited Diseases. McGrawHill. Inc: New York St. Louis 2001; pp. 3453-68.
50. Everts V, Hou WS, Rialland X, et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of nondigested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003; 73: 380-86.
51. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (/) mice. Bone 2009; 44: 199-07.
52. Dare SKL, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007; 40(1): 122-31.
53. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999; 14(10): 1654-63.
54. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci 1998; 95: 3453-58.
55. Yasuda Y, Kaleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005; 57: 973-93.
56. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006; 5: 785-99.
57. Rodan SB, Duong LT. Cathepsin K A new molecular target for osteoporosis. IBMS BoneKEy 2008; 5: 16-24.
58. Rothschild BM, Hershkovitz I, Dutour O. Clues potentially distinguishing lytic lesions of multiple myeloma from those of metastatic carcinoma. Am J Phys Anthropol 1998; 105(2): 241-50.
59. Seeman E. Advances in Therapeutics: Meeting Report from the 31st Annual Meeting of the American Society for Bone and Mineral Research: September, 2009 in Denver, Colorado. IBMS BoneKEy 2009; 6: 496-02.
60. Ochi Y, Yamada H, Mori H, et al. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 2011; 49(6): 1351-56.
61. Sato A, Dodo K, Makishima M, Hashimoto Y, Sodeoka M. Synthesis and evaluation of 2,3-dinorprostaglandins: DinorPGD1 and 13-epi-dinor-PGD1 are peroxisome proliferatoractivated receptor / dual agonists. Bioorganic & Medicinal Chemistry Letters 2013; 23: 3013-17.
62. Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 2011; 49(6): 1351-56.
63. Hamwi A, Ganem AH, Grebe C, et al. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy. Clin Chem Lab Med 2001; 39(5): 414-17.
64. Pennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. Bone Miner Res 2011; 26(2): 252-62.
65. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, Duong le T. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012; 27(3): 524-37.
66. Le GC, Bellahcene A, Bonnelye E, Gasser JA, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67(20): 9894-02.
67. Bromme D, Lecaille, F. Cathepsin K inhibitors for osteoporosis and potential off-target Effects. Expert Opin Investig Drugs 2009; 18(5): 585-600.
68. Lin, J. H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
69. Elise I, Kevin BP, Nathalie C, et al. The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. Bioorganic & Medicinal Chemistry Letters 2010; 20(3): 887-92.
70. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009; 86: 175-82.
71. Podgorski I. Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 2009; 1: 21-34.
72. Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem 2005; 48: 7535-43.
73. Clinical Trials. gov; A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00371670 [accessed on: May 29, 2013].
74. Runger TM, Adami S, Benhamou CL, Czerwiski E, Farrerons J, Kendler DL, Mindeholm L, Realdi G, Roux C, Smith V. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012; 66(3): 89-96.
75. Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol 2008; 73(1): 147-56.
76. Fleming FF, Yao L, Ravikumar PC, Funk L, Shook BC. NitrileContaining Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. J Med Chem 2010; 53(22): 7902-17.
77. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007; 40: 122-31.
78. Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor, ONO-5334, in postmenopausal osteoporosis-the OCEAN study. JBMR 2011; 26(6): 1303-12.
79. Engelke, K. Effects of the cathepsin K inhibitor, ONO-5334, on BMD as measured by 3D QCT in the hip and the spine after 12 months treatment. Presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, ON, Canada, October 2010. Available at: http://www.asbmr.org/ [accessed on 26 th May, 2013].
80. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging 2012; 7: 235-47.
81. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18: 923-28.
82. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. Journal of Bone and Mineral Research 2010; 5(5): 934-37.
83. Cusick T, Pennypacker B, Scott K, Duong L. Effects of odanacatib on bone mass, turnover and strength in the femoral neck of estrogen deficient adult Rhesus monkeys, in Proceedings of the American Society for Bone and Mineral Research Meeting (ASBMR '09), Denver, Colo, USA, 2009; J Bone Miner Res 24 (Suppl 1). Available at: http://www.asbmr.org/Meetings/PastAnnualMeetings.aspx [accessed on June 1, 2013].
84. J. Eisman, H. Bone, D. Hosking, and L. Duong. Odanacatib in the treatment of postmenopausal women with low bone mineral density: long-term continued therapy and resolution of effect, in Proceedings of the American Society for Bone and Mineral Research Meeting (ASBMR '09), Denver, Colo, USA, 2009; J Bone Miner Res 24 (Suppl 1). Available at: http://www.asbmr.org/Meetings/PastAnnualMeetings.aspx [accessed on June 1, 2013].
85. Merck halts Ph III trial of osteoporosis drug on success. Available at: http://www.natap.org/2012/newsUpdates/071312_02.htm [accessed on June 1, 2013].
86. AJ, Christopher W, Guillermo R, et al. The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial. Clin. Breast Cancer 2010; 10(6): 452-58.
87. Le T, Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. BoneKEy Reports 2012; 67. doi:10.1038/bonekey.2012.67.